A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.
Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.
This analysis compared drug survival rates of abrocitinib and dupilumab in the treatment of adults with eczema, with different benefits highlighted for both therapies.
Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.
Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.
Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.
Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.
In this analysis, investigators compared deucravacitinib in terms of patient-reported outcomes versus those of placebo and apremilast.
Study finds elevated HAMD-17 scores in PBC patients predict cirrhosis risk, with depressive symptoms linked to higher liver enzyme levels and worse UDCA response.
In this episode, hosts are joined by Muthiah Vaduganathan, MD, MPH, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials.
In this episode, hosts take a break from the ADCES meeting to discuss the latest news from Medtronic related to their Simplera CGM and their partnership with Abbott.
The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.
These data suggest benefits to pregnant mothers with this condition following early biologic intervention, with treatment leading to rapid refractory pustular psoriasis remission.
A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.
Results suggest discordance between FIB-4 and liver stiffness measurement for MASLD-related fibrosis risk stratification.
Interim analysis of STELLAR showed health-related quality of life domains were within a normal range after hematopoietic cell transplant for SCD.
The FDA approved epinephrine nasal spray (Neffy) for the emergency treatment of allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh at least 30 kg.
Despite these findings, additional research may be necessary to evaluate emerging therapies and prognostic factors in the management of chronic actinic dermatitis.
Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.
In this interview, Chovatiya spoke with the editorial team about the global prevalence findings on patients with seborrheic dermatitis and their implications.
Atopic dermatitis increases stress, depression, anxiety, and suicidal ideation, affecting patients' mental health, a recent study found.
A total of 82.3% of patients in the biosimilars group and 90.9% in the reference drug group achieved an ACR20 response.
Study finds 70% of atopic dermatitis patients using dupilumab continued for up to 5 years, but 23.8% discontinued primarily due to adverse events or ineffectiveness.
Positive topline results from the phase 3 VALIANT study show promise for pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
Nipocalimab led to a substantially higher percentage of live births at 32 weeks’ gestation or later without intrauterine transfusions than the historical benchmark.
In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.
Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.
On August 07, 2024, Novartis announced the FDA's accelerated approval of iptacopan for reducing proteinuria in primary IgAN based on interim data from APPLAUSE-IgAN.
Ferritin cutoffs of 30 and 45 ng/mL notably increase the rate of iron deficiency diagnoses.
These data point to differences between genders such as time to initiation of treatment, treatment choice, response to medication, adverse events, and adherence.
